English
ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: АСПЕКТЫ ДИАГНОСТИКИ И МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ
DOI: https://dx.doi.org/10.18565/therapy.2024.4suppl.162-185
Базовая структура инфографики соответствует следующим источникам:
Клинические рекомендации. Хроническая сердечная недостаточность. Российское кардиологическое общество, автономная некоммерческая организация «Национальное общество по изучению сердечной недостаточности и заболеваний миокарда», Общероссийская общественная организация «Общество специалистов по сердечной недостаточности». 2020. ID:156. Доступ: http://cr.rosminzdrav.ru/schema/156_1 (рубрикатор клинических рекомендаций Минздрава России).
Адаптировано со ссылками на использованную литературу
Литература
1. Клинические рекомендации. Российское кардиологическое общество, автономная некоммерческая организация «Национальное общество по изучению сердечной недостаточности и заболеваний миокарда», общероссийская общественная организация «Общество специалистов по сердечной недостаточности». 2020. ID: 156. Доступ: http://cr.rosminzdrav.ru/schema/156_1 (дата обращения – 01.03.2024). 2. The SOLVD Investigators; Yusuf S., Pitt B., Davis C.E. et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5): 293–302. https://doi.org/10.1056/NEJM199108013250501. PMID: 2057034. 3. Velazquez E.J., Morrow D.A., DeVore A.D. et al; PIONEER-HF Investigators. Angiotensinneprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–48. https://doi.org/10.1056/NEJMoa1812851. PMID: 30415601. Erratum in: N Engl J Med. 2019; 380(11): 1090. 4. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20): 1893–906. https://doi.org/10.1056/NEJMoa032292. PMID: 14610160. 5. Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002; 40(8): 1414–21. https://doi.org/10.1016/s0735-1097(02)02304-5. PMID: 12392830. 6. Dimopoulos K., Saukhe T.V., Coats A. et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol. 2004; 93(2–3): 105–11. https://doi.org/10.1016/j.ijcard.2003.10.001. PMID: 14975535. 7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316(23): 1429–35. https://doi.org/10.1056/NEJM198706043162301. PMID: 2883575. 8. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995; 273(18): 1450–56. PMID: 7654275. 9. Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999; 100(23): 2312–18. https://doi.org/10.1161/01.cir.100.23.2312. PMID: 10587334. 10. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10): 669–77. https://doi.org/10.1056/NEJM199209033271001. PMID: 1386652. 11. SOLVD Investigators; Yusuf S., Pitt B., Davis C.E. et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992; 327(10): 685–91. https://doi.org/10.1056/NEJM199209033271003. PMID: 1463530. 12. Государственный реестр лекарственных средств Минздрава России. Доступ: http://grls. rosminzdrav.ru (дата обращения – 01.03.2024). 13. Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362(9386): 772–76. https://doi.org/10.1016/S0140-6736(03)14284-5. PMID: 13678870. 14. Cohn J.N., Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23): 1667–75. https://doi.org/10.1056/NEJMoa010713. PMID: 11759645. 15. McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: The CHARM-Added trial. Lancet. 2003; 362(9386): 767–71. https://doi.org/10.1016/S0140-6736(03)14283-3. PMID: 13678869. 16. McMurray J.J., Packer M., Desai A.S. et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993–1004. https://doi.org/10.1056/NEJMoa1409077. PMID: 25176015. 17. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарата Юперио. РУ: ЛП-003532. Доступ: https://grls.rosminzdrav. ru/Grls_View_v2.aspx?routingGuid=a342c364-b9ff-4a72-8a79-f0bc9e607eed (дата обращения – 01.03.2024). 18. Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334(21): 1349–55. https://doi.org/10.1056/NEJM199605233342101. PMID: 8614419. 19. Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003; 91(2): 169–74. https://doi.org/10.1016/s0002-9149(02)03104-1. PMID: 12521629. 20. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet. 1999; 353(9146): 9–13. PMID: 10023943. 21. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10): 709–17. https://doi.org/10.1056/NEJM199909023411001. PMID: 10471456. 22. Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11–21. https://doi.org/10.1056/NEJMoa1009492. PMID: 21073363. 23. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008. https://doi.org/10.1056/NEJMoa1911303. PMID: 31535829. 24. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственных препаратов с МНН дапаглифлозин. Доступ: https://grls. rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=Дапаглифлозин&lf=&TradeNmR=&OwnerN ame=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered& orderType=desc&pageNum=1 (дата обращения – 01.03.2022). 25. Berg D.D., Jhund P.S., Docherty K.F. et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021; 6(5): 499–507. https://doi.org/10.1001/jamacardio.2020.7585. PMID: 33595593. PMCID: PMC7890451. 26. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet. 2010; 376(9744): 875–85. https://doi.org/10.1016/S0140-6736(10)61198-1. PMID: 20801500. 27. Swedberg K., Komajda M., Bohm M. et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012; 59: 1938–45. https://doi.org/10.1016/j.jacc.2012.01.020. PMID: 22617188. 28. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственных препаратов с МНН ивабрадин Доступ: https://grls. rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=Ивабрадин&lf=&TradeNmR=&OwnerName= &MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered&orderTy pe=desc&pageNum=1 (дата обращения – 01.03.2024). 29. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственных препаратов с МНН дигоксин. Доступ: https://grls. rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=дигоксин&lf=&TradeNmR=&OwnerName=& MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1 (дата обращения – 01.03.2024). 30. Tavazzi L., Maggioni A.P., Marchioli R. et al.; The GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomized, double-blind, placebo-controlled trial. Lancet. 2008; 372(9645): 1223–30. https://doi.org/10.1016/S0140-6736(08)61239-8. PMID: 18757090. 31. Cohn J.N., Archibald D.G., Ziesche S. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314 (24): 1547–52. https://doi.org/10.1056/NEJM198606123142404. PMID: 3520315.
